Results 1 to 10 of about 83,483 (295)

molIEreVIS: exploring and interpreting the evidence behind drug repurposing predictions [PDF]

Frontiers in Bioinformatics
IntroductionFinding new uses for existing drugs, known as drug repurposing, is a widely adopted drug development strategy in the pharmaceutical industry.
Amal Alnouri, Andreas Hinterreiter, Christian Steinparz, Labinot Bajraktari, Sebastian Burgstaller-Muehlbacher, Markus Bauer, Gregorio Alanis-Lobato, Marc Streit   +7 more
doaj   +2 more sources

Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review [PDF]

Drug Design, Development and Therapy
Abdulaziz H Al Khzem,1 Saad M Wali2 1Department of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, 31441, Eastern Province, Kingdom of Saudi Arabia; 2Pharmacology and Toxicology Department, College of ...
Al Khzem AH, Wali SM
doaj   +2 more sources

Does collective consciousness compromise during epidemics and pandemics? [PDF]

EAI Endorsed Transactions on Smart Cities, 2021
The ongoing pandemic, COVID-19, has received unprecedented global attention. Though a pathogen is essentially the causative agent, the dynamics of the cause-effect in major events like the ongoing COVID-19 pandemic is not ...
Anoushka Khanna, Namita I, Rina Chakrabarti, Prem Indraganti   +3 more
doaj   +1 more source

Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice

Pharmaceuticals, 2023
Paclitaxel is an anticancer agent efficacious in various tumors. There is large interindividual variability in drug plasma concentrations resulting in a wide variability in observed toxicity in patients.
Mirjana Radovanovic, Peter Galettis, Alex Flynn, Jennifer H. Martin, Jennifer J. Schneider   +4 more
doaj   +1 more source

Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment

Cells, 2022
Glioblastoma is a highly aggressive, invasive and treatment-resistant tumour. The DNA damage response (DDR) provides tumour cells with enhanced ability to activate cell cycle arrest and repair treatment-induced DNA damage.
Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael Fay, Bryan W. Day, Brett W. Stringer, Paul A. Tooney   +6 more
doaj   +1 more source

A Path to Real-World Evidence in Critical Care Using Open-Source Data Harmonization Tools

Critical Care Explorations, 2023
COVID-19 highlighted the need for use of real-world data (RWD) in critical care as a near real-time resource for clinical, research, and policy efforts.
Smith F. Heavner, PhD, RN, Wesley Anderson, PhD, Rahul Kashyap, MBBS, MBA, Pamela Dasher, BA, Ewy A. Mathé, PhD, Laura Merson, Philippe J. Guerin, MD, PhD, Jeff Weaver, MBA, Matthew Robinson, MD, Marco Schito, PhD, Vishakha K. Kumar, MD, MBA, Paul Nagy, PhD   +11 more
doaj   +1 more source

Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy

BMC Cancer, 2022
Background Platinum chemoresistance results in high-grade serous ovarian cancer (HGSOC) disease recurrence. Recent treatment advances using checkpoint inhibitor immunotherapy has not benefited platinum-resistant HGSOC.
Michelle W. Wong-Brown, Andre van der Westhuizen, Nikola A. Bowden   +2 more
doaj   +1 more source

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers

Pharmacology Research & Perspectives, 2021
Trial data support an absence of an exposure–survival relationship for pembrolizumab. As these relationships remain unexamined in a real‐world setting, we determined them in metastatic melanoma prospectively in an observational study.
Vishal Navani, Moira C. Graves, Giovana Celli Marchett, Hiren Mandaliya, Nikola A. Bowden, Andre van derWesthuizen   +5 more
doaj   +1 more source

Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review

Frontiers in Pharmacology, 2023
Background: Alzheimer’s disease (AD) is a debilitating neurodegenerative condition with few treatment options available. Drug repurposing studies have sought to identify existing drugs that could be repositioned to treat AD; however, the effectiveness of
Monika E. Grabowska, Annabelle Huang, Zhexing Wen, Bingshan Li, Wei-Qi Wei   +4 more
doaj   +1 more source

Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders

Pharmaceutics, 2022
Despite advances in pharmacology and neuroscience, the path to new medications for psychiatric disorders largely remains stagnated. Drug repurposing offers a more efficient pathway compared with de novo drug discovery with lower cost and less risk ...
Trang T. T. Truong, Bruna Panizzutti, Jee Hyun Kim, Ken Walder   +3 more
doaj   +1 more source